Gastroesophageal Reflux Disease (GERD) Therapeutics Market Gastroesophageal Reflux Disease Therapeutics Market By Drug Class (PPIs, H2 Receptor Antagonists, Antacids, Prokinetics, Mucosal Protectants); By Route of Administration (Oral, Intravenous); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Gastroesophageal Reflux Disease Therapeutics Market: P-CAB Adoption Raises Acid-Control Value

The Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market is estimated to reach USD 7.82 billion in 2025 and is projected to grow to USD 11.53 billion by 2032, expanding at a CAGR of 5.7%, driven by rising GERD prevalence, proton pump inhibitors and H2 blockers, according to Strategic Market Research.

 

The gastroesophageal reflux disease therapeutics market operates as a large, recurring pharmaceutical business supported by a smaller, higher-value procedural segment. Proton pump inhibitors, H2-receptor antagonists, antacids and alginate products account for most treatment events because patients can access many of these therapies without specialist involvement. Prescription potassium-competitive acid blockers are adding a differentiated branded category, while fundoplication, magnetic sphincter augmentation and endoscopic procedures remain concentrated among patients with objectively confirmed disease, persistent symptoms, suitable anatomy or a preference to avoid long-term medication. The commercially defensible classification is therefore a drug-dominant market with a selective procedural pathway rather than a purely pharmaceutical or surgery-led market.

 

Revenue is generated through OTC purchases, repeat prescriptions, maintenance therapy, treatment escalation, diagnostic evaluation and procedure-linked device use. This structure creates very different economics across the market. Generic PPIs deliver high volumes but face substitution and price competition. Branded P-CABs offer stronger differentiation but require formulary access and substantial rebates. Procedures carry higher expenditure per patient but depend on specialist referrals, objective reflux testing, hospital capacity and payer authorization. NIDDK continues to position lifestyle measures and medicines as standard management, with surgery considered in selected cases rather than as a broad first-line alternative.

 

A Large Disease Pool Does Not Equal a Fully Addressable Market

The latest Global Burden of Disease-based analysis estimated 825.6 million prevalent GERD cases and approximately 324.1 million incident cases worldwide in 2021. Global prevalent cases increased by about 80% between 1990 and 2021, primarily reflecting population growth, ageing and changes in disease exposure rather than an equivalent expansion in prescription-treated patients. These figures establish the epidemiological ceiling for the market, not the diagnosed, treatment-eligible or commercially treated population.

South Asia represented the largest regional patient pool, with approximately 244.46 million prevalent cases in 2021. India alone accounted for roughly 194 million prevalent and 76.32 million incident cases, while China recorded approximately 81.33 million prevalent cases. The same analysis placed East Asia at around 84.45 million prevalent cases, substantially below the 130–150 million range sometimes cited in secondary summaries. Tropical Latin America recorded the highest age-standardized prevalence rate, while East Asia had the lowest, demonstrating why absolute patient numbers and population-adjusted disease intensity must be assessed separately.

Commercial conversion is materially lower than these headline figures. Many people experience intermittent symptoms, self-medicate through OTC channels, improve after short treatment courses or never receive objective confirmation. Symptom-defined populations can also include functional heartburn, reflux hypersensitivity and other conditions that do not respond to additional acid suppression. In lower-access markets, affordability, limited specialist availability and uneven diagnostic coverage create further leakage between prevalence and treatment revenue.

The United States remains one of the most monetizable markets because of high pharmacy access, broad use of acid-suppressing therapy and an established specialist infrastructure. NIDDK estimates that about 20% of people in the United States have GERD. This supports the broad one-in-five burden statement, but it does not validate the more specific claim that 66 million U.S. adults have formally diagnosed GERD. The commercially relevant population includes diagnosed patients, recurring OTC users, prescription users and procedure-eligible subgroups, which cannot be derived by applying the 20% rate directly to the adult population.

Weight management is commercially relevant because overweight and obesity increase the likelihood of persistent reflux and can raise treatment intensity. Clinical guidance recommends weight loss for affected patients who are overweight, avoiding meals close to bedtime and elevating the upper body for nocturnal symptoms. These measures can reduce medication dependence for some patients, but their inconsistent adoption keeps pharmacological treatment central to long-term market demand.

 

Generic PPIs Retain Volume Leadership but Offer Limited Pricing Power

Proton pump inhibitors remain the principal pharmaceutical segment because they provide stronger acid suppression and better healing of reflux-related esophageal damage than H2 blockers. Omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole and dexlansoprazole give prescribers and patients a wide range of generic, branded and OTC choices. Current guidance generally supports an initial four- to eight-week or eight-week PPI trial for patients with typical symptoms before additional testing is considered.

The size of this recurring prescription channel is visible in Medicare utilization. The attached CMS-based assessment identified approximately 23.64 million pantoprazole claims and 48.39 million standardized 30-day fills within Medicare Part D during 2023. These figures include uses outside GERD and do not represent unique patients, but they demonstrate how a single mature PPI can generate tens of millions of annual treatment events.

High utilization does not automatically produce attractive manufacturer margins. Generic substitution, pharmacy purchasing contracts, multiple active ingredients and OTC availability reduce pricing power. Suppliers compete through manufacturing scale, distribution reach, reliable supply and preferred pharmacy positioning rather than substantial clinical differentiation. Oral delayed-release tablets account for the broadest demand, while intravenous pantoprazole remains a narrower hospital category used for short-term management when oral administration is inappropriate.

H2 blockers and antacids serve the intermittent and lower-intensity end of the treatment pathway. Famotidine, cimetidine and other H2 antagonists provide an alternative for patients who do not require continuous PPI-level suppression. Antacids and alginate-containing products create substantial OTC activity but are fragmented across brands, private labels and retail channels. Their accessibility also reduces the proportion of symptomatic individuals entering formal prescription datasets.

The November 2025 FDA approval of reformulated ranitidine returned the H2 blocker to the U.S. market after a five-year absence. The formulation and storage requirements were redesigned to address previous NDMA impurity concerns. Its return expands competition within the H2RA category, although manufacturers must rebuild prescriber and consumer confidence while competing against well-established famotidine products.

 

P-CABs Create the Main Premium Pharmaceutical Opportunity

Potassium-competitive acid blockers are changing the value profile of GERD treatment by introducing a branded alternative to mature PPIs. The FDA approved Phathom Pharmaceuticals’ VOQUEZNA, or vonoprazan, in November 2023 for healing and maintaining healing of erosive esophagitis and associated heartburn in adults. In July 2024, the indication was expanded to include relief of heartburn associated with non-erosive GERD. This gave the product access to both endoscopically visible disease and the much broader non-erosive population.

Vonoprazan’s commercial differentiation is strongest in patients requiring rapid, potent or sustained acid suppression. In the pivotal erosive-esophagitis program, vonoprazan achieved healing in 93% of patients compared with 85% for lansoprazole. Among patients with more severe Los Angeles grade C or D disease, healing rates were 92% and 72%, respectively. The difference provides a clinically meaningful positioning argument in severe disease, although generic PPIs remain adequate and substantially less expensive for many patients.

Adoption has moved beyond an early launch signal. Phathom reported approximately 268,000 total VOQUEZNA prescriptions during Q1 2026, representing 115% year-over-year growth, and approximately 1.35 million cumulative prescriptions as of April 17, 2026. Q1 2026 net revenue reached USD 58.3 million, compared with USD 28.5 million one year earlier. These figures cover the VOQUEZNA product family and are not exclusively attributable to GERD because vonoprazan also has approved Helicobacter pylori treatment uses.

Payer execution will determine how much of the eligible population moves from generic PPIs to branded P-CAB treatment. Approximately 63% of VOQUEZNA prescriptions in Q1 2026 were covered by insurance, while covered prescriptions increased 91% year over year. Phathom maintained 2026 net-revenue guidance of USD 320–345 million, an expected gross margin of approximately 80% and a gross-to-net discount range of 55–59%. The discount level illustrates the commercial cost of formulary positioning, rebates and patient-access programs even when a product has strong gross product economics.

The P-CAB segment is therefore positioned as the clearest premium-growth category rather than an immediate replacement for the entire PPI market. Uptake is likely to concentrate among patients with erosive disease, incomplete PPI response, adherence difficulties, recurrent symptoms or physician preference for stronger acid control. Generic PPIs will continue to lead treatment volume because of familiarity, affordability and broad reimbursement.

 

Persistent Symptoms Expand Testing Before They Expand Treatment

Patients who continue to report symptoms after an adequate PPI trial do not automatically represent candidates for higher drug doses, a P-CAB or surgery. Current clinical approaches increasingly emphasize treatment optimization and objective confirmation because persistent heartburn or regurgitation may reflect non-acid reflux, reflux hypersensitivity, functional heartburn, motility disorders or incorrect medication use.

The 2022 ACG guideline recommends diagnostic endoscopy when classic symptoms do not respond adequately to an eight-week empiric PPI trial or return after treatment discontinuation. In appropriate patients, ambulatory pH or pH-impedance monitoring can establish whether reflux is continuing, while esophageal manometry helps assess motility and procedural suitability. This creates a supporting commercial pathway for endoscopy systems, reflux-monitoring equipment, disposable catheters and specialist services.

Commercially, better phenotyping can reduce inappropriate escalation but increase spending on diagnostic workups. Pharmaceutical companies benefit when testing identifies true acid-mediated disease suitable for continued suppression. Procedure suppliers benefit when objectively confirmed patients are referred for anatomical treatment. Conversely, confirmation of functional heartburn can remove patients from both advanced drug and procedural funnels.

 

Fundoplication Remains the Procedural Benchmark

Anti-reflux surgery addresses the anatomical barrier rather than relying exclusively on acid suppression. Laparoscopic fundoplication remains the principal established operation, while magnetic sphincter augmentation and endoscopic fundoplication offer alternatives for selected patients. These procedures compete with chronic medication in a narrow subgroup but also complement the drug pathway because most patients receive medical therapy before referral.

Current procedural data are considerably less complete than pharmaceutical utilization data. The UK National Hiatal Surgery Registry reported 279 complete primary fundoplication cases in its 2023 dataset. Approximately 95% were performed laparoscopically, 32% were day cases and the median waiting time was 183.5 days. The registry is voluntary and does not represent total UK procedure volume, but the long waiting interval indicates that specialist capacity can delay revenue conversion even when demand is present.

Magnetic sphincter augmentation represents a smaller implant-linked opportunity. The same registry contained 85 complete LINX cases from eight participating organizations. About 76.5% were conducted as day cases, compared with 32% of recorded fundoplications, and the median waiting time was 158 days. Its outpatient profile can reduce inpatient resource use and support ambulatory adoption, although implant purchasing, surgeon training, anatomical selection and payer approval limit the addressable population.

Endoscopic approaches are also gaining institutional relevance. The 2025 ASGE guideline addresses transoral incisionless fundoplication, combined hiatal hernia repair with TIF and other endoscopic anti-reflux therapies. Guideline recognition supports gastroenterologist and hospital interest, but these interventions remain selective rather than broad substitutes for PPIs. Their commercial expansion depends on durable outcomes, consistent reimbursement and the establishment of referral pathways between gastroenterologists, surgeons and endoscopy units.

Johnson & Johnson MedTech participates through the LINX Reflux Management System, while Merit Medical supplies the EsophyX platform used for TIF procedures. These businesses differ fundamentally from oral-drug commercialization. Device suppliers must build trained-center networks, support procedural education and secure hospital purchasing and reimbursement, whereas pharmaceutical companies focus more heavily on prescriber reach, pharmacy access and formulary placement.

 

North America Combines Mature Volume with Premium-Drug Monetization

High-income North America accounted for approximately 45.18 million prevalent GERD cases in 2021. The region combines widespread generic access with a large OTC channel, specialist diagnostic capacity and the strongest publicly visible commercial uptake of branded vonoprazan. Although the GBD analysis recorded declining age-standardized prevalence and incidence trends in high-income North America from 1990 to 2021, the absolute patient pool remains large enough to support substantial recurring therapy demand.

North American growth will depend less on first-time access to PPIs and more on treatment switching, premium P-CAB adoption, insurance coverage and selective procedural expansion. Generic manufacturers face intense price competition, while differentiated suppliers must prove value against inexpensive and familiar alternatives. Payer controls, gross-to-net discounts and prior authorization will remain central to realized branded revenue.

 

South Asia Offers the Largest Patient Volume but Higher Commercial Leakage

South Asia’s approximately 244.46 million prevalent cases create the largest regional epidemiological opportunity. India accounts for most of this burden, with roughly 194 million estimated cases. However, self-medication, fragmented diagnosis, variable physician access and high sensitivity to out-of-pocket cost mean that the region’s patient volume cannot be converted directly into a comparable pharmaceutical revenue share.

The near-term opportunity is strongest for competitively priced oral generics and OTC products distributed through broad retail networks. Premium P-CAB adoption will be more concentrated in urban private-care settings and among patients able to pay for differentiated therapy. Expansion of gastroenterology services and endoscopy capacity can improve diagnosis, but procedural anti-reflux treatment is likely to remain a small specialist segment relative to medication use.

 

East Asia and High-Income Asia Pacific Require Separate Strategies

East Asia recorded approximately 84.45 million prevalent cases in 2021 but had the lowest age-standardized prevalence rate among GBD regions. China represented approximately 81.33 million cases, demonstrating that population size can create high absolute demand even when disease rates are comparatively low. High-income Asia Pacific, by contrast, recorded the strongest increase in age-standardized GERD burden between 1990 and 2021, supporting continued demand for advanced acid-control products in markets with established reimbursement and specialist access.

Japan and other Asian markets also have longer experience with P-CAB therapy than the United States, which can support physician familiarity with the class. Competitive positioning in the region will depend on local pricing, approved indications, reimbursement and the strength of domestic generic and branded manufacturers rather than a uniform Asia-Pacific strategy.

 

Europe Remains Guideline- and Reimbursement-Led

Western Europe accounted for approximately 48.52 million prevalent cases in the attached GBD-based assessment. Public health systems generally reinforce stepwise management, beginning with lifestyle measures and acid suppression before objective testing and surgery. This supports stable generic demand but can slow the uptake of premium drugs and procedures that require additional evidence or specialist referral.

European procedural opportunities are concentrated in experienced foregut centers and selected endoscopy units. The UK registry’s waiting times demonstrate that public-system capacity can be as important as patient eligibility. Suppliers must therefore consider reimbursement, center throughput and workforce availability rather than relying on prevalence alone.

 

Competitive and Commercial Outlook

Competition in the Gastroesophageal Reflux Disease Therapeutics Market is shifting from a mature contest among generic PPIs and OTC acid reducers toward a broader race involving branded P-CABs, regional licensing partnerships and minimally invasive procedural platforms. Generic omeprazole, pantoprazole, esomeprazole, lansoprazole and rabeprazole still account for most treatment volume, but their widespread availability limits manufacturer pricing power. The strongest commercial differentiation is now concentrated among companies introducing faster and more sustained acid suppression or procedures intended to reduce dependence on long-term medication.

Phathom Builds the First Commercial-Scale U.S. P-CAB Franchise

Phathom Pharmaceuticals currently holds the strongest publicly documented commercial position in the U.S. premium GERD drug segment through VOQUEZNA, or vonoprazan. The product generated USD 175.1 million in net revenue during 2025, representing a 217% increase from USD 55.3 million in 2024. Approximately 273,000 prescriptions were filled during Q4 2025, up 24% sequentially, while cumulative prescriptions exceeded 1.1 million by February 2026.

Momentum continued during Q1 2026, when Phathom reported approximately 268,000 prescriptions, a 115% year-over-year increase, and USD 58.3 million in net revenue, compared with USD 28.5 million in Q1 2025. Cumulative prescriptions reached approximately 1.35 million by April 17, 2026. Among the company’s 3,000 highest-prescribing gastroenterologists, VOQUEZNA represented approximately 30% of new-to-brand prescriptions compared with PPIs, indicating that the product is gaining meaningful share when clinicians decide to switch or initiate a branded therapy.

Insurance conversion remains the largest constraint on this growth. Approximately 63% of Q1 2026 prescriptions were insurance-covered, although covered prescriptions increased 91% year over year. Phathom expects USD 320–345 million in net revenue for 2026, an approximately 80% gross margin and a 55–59% gross-to-net discount. The large discount range demonstrates how rebates, formulary agreements, copay assistance and other access expenses reduce realized revenue from branded acid-suppression products. Phathom still recorded a Q1 2026 net loss of USD 30.4 million, although this was considerably lower than the USD 94.3 million loss recorded one year earlier.

The underlying economics also involve Takeda Pharmaceutical, which originally developed vonoprazan and licensed the U.S., European and Canadian rights to Phathom in 2019. The agreement includes potential sales milestone payments of up to USD 250 million and royalties averaging in the low double digits on net sales. Phathom recorded USD 5.8 million in Takeda royalty expense during Q1 2026, compared with USD 2.9 million one year earlier. U.S. regulatory exclusivity for the VOQUEZNA product family extends through May 3, 2032, providing Phathom with a meaningful commercial protection period while competing P-CABs progress toward the market.

 

Tegoprazan Could Introduce Direct U.S. P-CAB Competition

Sebela Pharmaceuticals, through its Braintree Laboratories business, is developing tegoprazan as the most advanced potential U.S. competitor to vonoprazan. Sebela submitted a New Drug Application to the FDA in January 2026 covering heartburn associated with non-erosive reflux disease, healing of erosive esophagitis and maintenance of erosive-esophagitis healing. The company has stated that it anticipates a U.S. regulatory decision in January 2027, although approval timing remains dependent on the FDA review.

The U.S. Phase 3 program included approximately 1,250 patients with erosive esophagitis, including 463 patients with severe Los Angeles grade C or D disease, and a separate 633-patient non-erosive reflux disease study. Tegoprazan demonstrated superiority over lansoprazole for healing at weeks two and eight in the company’s reported Phase 3 results, while the non-erosive study showed significant improvement over placebo in heartburn-free days. Tegoprazan has already received marketing authorization in 23 countries, including South Korea and China, which provides Sebela with clinical and commercial experience before a potential U.S. launch.

Approval would change the U.S. market from a single-product P-CAB category into a direct branded competition between Phathom and Sebela. This could increase physician awareness and class adoption, but it would also intensify formulary negotiations, contracting and rebate pressure. Sebela would need to secure payer coverage and prescriber access quickly because VOQUEZNA will have several years of commercial experience, an established gastroenterology sales force and accumulated refill data by the time tegoprazan could enter.

 

Daewoong and Sun Pharma Expand Fexuprazan Across Asia

Daewoong Pharmaceutical is building another important P-CAB franchise through Fexuclue, or fexuprazan. The product was launched in South Korea in July 2022, and Daewoong reported that sales had exceeded KRW 100 billion in its 2024 financial update. The company has used regional licensing and supply agreements to extend the product beyond its domestic market rather than building every commercial organization internally.

Sun Pharmaceutical Industries launched fexuprazan in India under the Fexuclue brand in April 2025 after obtaining manufacturing and commercialization rights from Daewoong. Under the agreement, Daewoong is eligible for upfront payments, milestones and royalties. An Indian Phase 3 study reported that more than 95% of treated patients achieved erosive-esophagitis healing by eight weeks. The launch gives Sun Pharma a differentiated prescription product in a market otherwise dominated by inexpensive PPIs and OTC acid reducers.

Fexuprazan’s progress also demonstrates how Asian P-CAB developers are using multinational partnerships to compete with Western-originator brands. Daewoong supplies the molecule and development platform, while companies such as Sun Pharma contribute local manufacturing, regulatory execution, physician reach and pharmacy distribution. This structure can accelerate geographic expansion without requiring Daewoong to fund a full commercial infrastructure in every country.

 

Generic PPIs Remain the Largest Competitive Barrier

Despite the investment moving into P-CABs, generic PPIs remain the main commercial barrier for every branded entrant. U.S. Medicare Part D recorded approximately 23.64 million pantoprazole claims and 48.39 million standardized 30-day fills in 2023. These figures include indications beyond GERD and cover Medicare beneficiaries rather than the entire market, but they demonstrate the enormous recurring volume available to a single generic molecule.

Generic competition is fragmented among numerous manufacturers rather than concentrated in one dominant branded company. Supplier differentiation is based mainly on price, manufacturing scale, reliable supply, pharmacy contracts and dosage-form availability. This reduces the ability of branded PPIs such as Nexium and Dexilant to maintain premium positioning once therapeutically equivalent alternatives become widely available.

OTC competition further limits prescription conversion. Prilosec OTC, Nexium 24HR, Pepcid AC, Zantac 360, Gaviscon and Tums compete for patients who self-manage intermittent heartburn without entering the specialist treatment pathway. The return of reformulated ranitidine to the U.S. market in November 2025 adds another acid-reducing option after its five-year absence, although manufacturers will have to overcome residual safety perceptions associated with the earlier NDMA-related withdrawal.

Branded P-CAB companies must therefore establish value in patients who remain symptomatic, have erosive disease, require stronger nocturnal control or prefer dosing that is less dependent on meal timing. Competing only on general acid suppression would leave these products vulnerable to inexpensive generic substitution.

 

Procedural Companies Compete for a Smaller High-Value Patient Pool

Johnson & Johnson MedTech participates in the procedural market through the Ethicon LINX Reflux Management System. LINX generates implant-linked revenue from selected patients seeking an alternative to fundoplication or long-term medication. The UK National Hiatal Surgery Registry contained 85 completed LINX cases in 2023, with 76.5% performed as day cases, compared with 32% of recorded fundoplications. These figures do not represent total national utilization, but the outpatient profile supports the device’s potential fit with ambulatory surgical models.

Merit Medical strengthened its GERD position by acquiring the EsophyX Z+ device and related assets from EndoGastric Solutions in July 2024. The transaction involved approximately USD 105 million in cash consideration and gave Merit control of the device used in the TIF 2.0 procedure. Merit subsequently integrated manufacturing, distribution and sales into its Endotek portfolio and reported that 2025 sales benefited from increased EsophyX Z+ utilization, although the company has not publicly separated GERD-device revenue from its wider endoscopy business.

Merit’s strategy depends on more than direct device sales. The company provides recurring physician-training programs covering patient selection, device operation and the TIF and combined cTIF procedures. Training is commercially important because adoption requires gastroenterologists, surgeons, hospitals and payers to agree on referral criteria and treatment sequencing.

The procedural segment has higher revenue per treated patient than generic pharmacotherapy but faces a narrower eligible population and longer conversion cycle. Objective reflux testing, anatomical assessment, payer authorization, surgeon or endoscopist training and facility capacity all influence adoption. Device companies must consequently build specialized treatment centers rather than relying on broad retail or pharmacy distribution.

 

Competitive Positioning Through 2032

Phathom currently has the strongest U.S. branded-drug position, supported by first-mover advantage, rapidly rising prescriptions and regulatory exclusivity through May 2032. Its main commercial vulnerability is the cost of maintaining insurance coverage and prescription growth against low-cost PPIs.

Sebela represents the most immediate potential U.S. challenger. A successful tegoprazan approval could expand the P-CAB class while creating direct competition for gastroenterology prescriptions, payer contracts and severe-disease positioning. Daewoong and Sun Pharma provide evidence that P-CAB competition is already becoming geographically diverse, particularly in South Korea and India.

Generic PPI manufacturers will continue to control the largest treatment volumes, while OTC companies will retain patients with intermittent or self-managed symptoms. J&J MedTech and Merit Medical will compete for the smaller group progressing toward implant-based or endoscopic treatment.

The market is therefore developing into four competitive tiers:

• High-volume, low-margin generic PPIs and H2 blockers.

• Consumer-led OTC antacids, alginates and acid suppressors.

• Premium recurring P-CAB therapy led by Phathom, with Sebela, Daewoong and Sun Pharma strengthening competition.

• High-value but low-volume procedural platforms led by J&J MedTech and Merit Medical.

 

Gastroesophageal Reflux Disease (GERD) Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 7.82 Billion
Revenue Forecast in 2032	USD 11.53 Billion
Overall Growth Rate	CAGR of 5.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Drug Class	Proton Pump Inhibitors (PPIs); H2 Receptor Antagonists; Antacids; Prokinetics; Mucosal Protectants
By Route of Administration	Oral; Intravenous
By Distribution Channel	Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Rising GERD Prevalence	Increasing global GERD burden, ageing populations, lifestyle-related risk factors, and growing diagnosis rates are supporting long-term demand for acid-control therapies.
Market Drivers – Growth of Premium Acid-Control Therapies	Adoption of potassium-competitive acid blockers (P-CABs) is creating a higher-value treatment segment for patients requiring stronger or more sustained acid suppression.
Market Drivers – Expansion of Healthcare Access and Awareness	Improved patient awareness, pharmacy accessibility, specialist consultations, and increasing healthcare expenditure are supporting GERD treatment adoption.
Customization Option	Available upon request